title: [BCG maintenance treatment: an optimal scheme?].
authors.affiliation: Service d'urologie de l'hôpital Cochin Port-Royal, faculté de médecine Paris Descartes, université Paris V, Assistance publique-Hôpitaux de Paris, 27, rue du Faubourg-Saint-Jacques, 75679 Paris cedex 14, France; Department of urology, Weill Cornell medical college, New York-Presbyterian hospital, New York, NY, États-Unis. Electronic address: evanguelosxylinas@hotmail.com.
authors.forename: E
authors.initials: E
authors.lastname: Xylinas
authors.affiliation: Department of urology, Weill Cornell medical college, New York-Presbyterian hospital, New York, NY, États-Unis.
authors.forename: S F
authors.initials: SF
authors.lastname: Shariat
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D001500:BCG Vaccine / Q000627:therapeutic use*; D006801:Humans; D060046:Maintenance Chemotherapy; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
chemical_list: D000276:Adjuvants, Immunologic; D001500:BCG Vaccine
keywords: BCG; Entretien; Maintenance; Non-muscle invasive bladder cancer; Progression; Recurrence; Récidive; Survie; Survival; Tumeur de la vessie n’infiltrant pas le muscle